Annual Report under Regulation-34 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015 for the financial year ended 31st March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Panchsheel Organics Limited has submitted its Annual Report for the financial year ended 31st March 2025, along with the notice for its 36th Annual General Meeting (AGM) to be held on 30th September 2025 via video conferencing. The company is an ISO-certified, GMP-approved pharma manufacturer and exporter of Active Pharma Ingredients (APIs), intermediates, and formulations, with over three decades of experience and manufacturing units in Indore. The Board has recommended a final dividend of Rs. 0.80 per share (8%) for FY24-25. The AGM also seeks shareholder approval to appoint M/s. Vijay S. Tiwari & Associates as the new Secretarial Auditor for a five-year term (FY 2025-26 to FY 2029-30) and to regularize three additional directors.
Routine annual compliance filing. The proposed 8% dividend is a positive signal for income-seeking shareholders, while the director appointments and secretarial auditor change reflect standard governance housekeeping with no material impact on stock price expected.